Savient makes executive appointments
This article was originally published in Scrip
Savient Pharmaceuticals is strengthening its management team with three new appointments as it begins the commercial launch of its gout therapy Krystexxa (pegloticase). Louis Ferrari will join as senior vice-president of North America commercial, Christine Mikail will become senior vice-president of corporate development and Stephen Davies becomes chief information officer and group vice president. Mr Ferrari was previously as vice-president of oncology and nephrology, sales and marketing at Centocor Ortho Biotech; Ms Mikail served as vice-president, general counsel and secretary for ImClone Systems; while Mr Davies was also previously at ImClone, where he as vice-president of information technology.
You may also be interested in...
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.
Non-CE-marked products on the EU market, virtual notified body audits, free standards and the Commission bid to pause the MDR. March has seen unprecedented developments as COVID-19 has railroaded through the sector decimating regulatory rules and plans.